Mycobacterium abscessus is a rapidly growing, multidrug-resistant organism, and has emerged as an opportunistic pathogen responsible for an increase in mortality especially in cystic fibrosis (CF) patients. There are limited chemotherapeutic options available for the treatment of infections caused by M. abscessus, mainly because of its resistance to many available antibiotics, including most anti-tubercular drugs. The need for novel and effective chemotherapeutic agents with a novel mode of action cannot be overemphasized. We recently reported that some indole-2-carboxamides (I2Cs) showed potent activity against M. abscessus. Two lead compounds, 1 and 2, showed potent in vitro activity against a range of M. abscessus isolates and in infected macrophages. In addition, compound 2 displayed an acceptable ADME profile and a selectivity index of 64-128. The mode of action of the I2Cs is believed to be associated with the mycolic acid transporter MmpL3 (figure 1) as evidenced by resistance caused by an A309P mutation in the gene encoding for that protein. Biochemical analyses showed that compounds 1 and 2 inhibit the transport of trehalosemonomycolate (TMM), causing the loss of trehalosedimycolate (TDM) production and cancelling mycolylation of arabinogalactan, a major structural component of the mycobacterial cell wall. The I2Cs thus represent a new class of chemical structures active against M. abscessus that may offer promise as possible treatment options for M. abscessus infection in CF patients.

Indole-2-carboxamides (I2Cs) targets mycolic acid transport and offer a potential treatment for Mycobacterium abscessus infections

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.